Copyright medicaldialogues
New Delhi: Sun Pharma has kept its options open on enhancing its manufacturing footprint in the U.S., even as the U.S. administration's 100% tariff on branded and patented medicines has created uncertainty for global drugmakers.During an analyst call, Richard Ascroft, CEO for Sun Pharma’s North America business, said the company already has a manufacturing footprint in the U.S.."We are kind of constantly assessing that manufacturing footprint, and we are open to considering this in the US in due time," he said, when asked if the drug maker is open to localised manufacturing in the US in the wake of high tariffs.The company is open for all options, he said without sharing any details.Ascroft noted that the tariff situation remains "very fluid and uncertain", and it is hard for the company to determine the impact it could have on its generics or innovative medicines portfolio at this time.As per PTI, Sun Pharma Executive Chairman Dilip Shanghvi said the company remains on track to launch UNLOXCYT, an FDA-approved treatment for advanced skin cancer, in the US in the second half of FY26.Read also: POSITIVE Trial: Tildrakizumab Significantly Improves Quality of Life in Psoriatic DiseaseThe company is also planning to file ILUMYA psoriatic arthritis SPLA during the second half of FY26, he added.The company continues to invest in building a R&D pipeline of its innovative medicines business, Shanghvi stated.Read also: Sun Pharma Gets CDSCO Panel Approval to Conduct Phase III Study of Oral SemaglutideSun Pharma is a specialty generics company with a presence in specialty, generics and consumer healthcare products. Sun Pharma’s global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. Its manufacturing facilities are spread across six continents. Read also: Sun Pharma appoints Jeremy Allen as Vice President, Corporate Affairs for North America
